Articles related to BLOOD CANCERS

Epcoritamab represents a significant breakthrough in the treatment of Richter syndrome, showcasing promising results in patients who have exhausted other therapeutic avenues. Its unique bispecific action heralds a new era in hematologic malignancy management.

Recent advances in CAR T-cell therapy show significant promise in treating both blood cancers and solid tumors, offering durable responses and extended survival rates for patients previously facing limited options.

Discover how system failures at Messino Cancer Centers have led to a critical decision impacting patient care. Learn more about this significant development and its implications for healthcare delivery.

Discover how CRISPR-engineered CD45 CAR T-cells could alter the treatment landscape for various blood cancers, offering a more versatile and less risky approach.

Uncover the potential of nivolumab and axicabtagene ciloleucel as they showcase promising results in the latest lymphoma trials, potentially reshaping the standard of care for these malignancies.

The MAJIC-PV study offers new insights into the use of ruxolitinib for polycythemia vera patients intolerant to hydroxycarbamide, emphasizing its role in extending survival and improving response rates.